Document is current
Any future updates will be listed below
-
Authors
Hartwell, Emily E. http://orcid.org/0000-0002-5137-9714
Jinwala, Zeal
Milone, Jackson
Ramirez, Sarah
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Kember, Rachel L. http://orcid.org/0000-0001-8820-2659
-
Funding
Funding for this research was provided by:
U.S. Department of Veterans Affairs (IK2 CX002336, VISN4 MIRECC, IK2 CX002336, VISN1 MIRECC, I01 BX004820, VISN4 MIRECC, VISN4 MIRECC)
N/A
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA037974, R01DA058862)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (K01AA028292)
- License Information
-
More Information
Article History
Received: 22 January 2024
Revised: 7 June 2024
Accepted: 28 June 2024
First Online: 23 July 2024
Competing interests
: HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, Enthion Pharmaceuticals, and Clearmind Medicine; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics. JG and HRK hold U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. Other authors have nothing to disclose.
